DGAP-News

Press Release: 4SC announces financial results for the first nine months and the third quarter of 2014

DGAP-News: 4SC AG / Key word(s): 9-month figures/Quarter Results
Press Release: 4SC announces financial results for the first nine
months and the third quarter of 2014

06.11.2014 / 07:30

---------------------------------------------------------------------

Press release

4SC announces financial results for the first nine months and the third
quarter of 2014

Planegg-Martinsried, Germany, 6 November 2014 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today published the
financial results of the 4SC Group for the first nine months of 2014 (1
January - 30 September 2014). A public telephone conference in English will
be held today at 3:00 pm CET (9:00 am EST).

Key operating events in research and development in Q3 2014 and beyond:

- 4SC Discovery GmbH: Funds received for researching new epigenetic
cancer drugs with collaboration partner CRELUX (July 2014).

- Resminostat: Successful completion of Phase I and start of the
randomised Phase II of the clinical trial being conducted by the
Company's Japanese partner Yakult Honsha on Asian patients with liver
cancer (HCC). Safety and tolerability confirmed (September 2014).

- Resminostat: Safety and tolerability demonstrated in Asian patients
with non-small-cell lung cancer (NSCLC) in Phase I of the clinical
trial being conducted by 4SC's Japanese partner Yakult Honsha; Phase II
started (October 2014).

- Resminostat: Patent for the resminostat manufacturing process granted
in the USA. Overall, this means that the production process for the
compound is protected until 2029 in almost all key markets around the
world (October 2014).

Key financial figures for the first nine months of 2014:

- Revenue up 66% to EUR 6.18 million (9M 2013: EUR 3.72 million)

- Operating loss (EBIT) reduced by 25% to EUR 6.21 million (9M 2013: EUR
8.25 million); earnings per share increased accordingly to EUR -0.12
(9M 2013: EUR -0.16)

- Solid third quarter: 25% improvement in revenue; operating loss up 12%
due to increased cost of sales and additional development expenses in
the manufacturing process for resminostat

- 4SC AG: Draw-down of the second tranche of convertible bonds in the
nominal amount of EUR 0.5 million as part of the financing agreement
with Yorkville and draw-down of a second tranche of EUR 2.0 million
from the shareholder loan from Santo Holding (September 2014).

Enno Spillner, CEO of 4SC AG, commented:

"We are pleased with our performance in the third quarter. The encouraging